Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
|Slideshows|April 18, 2018
6 New Drugs for Neurologists
Author(s)Susan Kweskin
Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.
Advertisement
Newly approved treatments for several neurologic disorders-including various types of pain, generalized myasthenia gravis, and Parkinson Disease-will be topics of discussion at AAN 2018. Here’s a brief overview of those medications FDA approved within the past 6 months.
Advertisement
Related to this article
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.
The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and nonmotor symptoms in Parkinson disease.
New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Ocrelizumab Shows MRI Benefits vs Fingolimod in Phase 3 Pediatric-Onset Multiple Sclerosis Study
2
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
3
FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis
4
New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy
5